Thursday, November 12, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

ServiceNow Partnerships Deepen AI Workflow Role Across Supply Chain And HR

View original at finance.yahoo.com
ServiceNow Partnerships Deepen AI Workflow Role Across Supply Chain And HR Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • ServiceNow sits at the center of a broad shift toward platforms that connect workflows across IT, operations, and business functions

    60% confidence

  • Expanding into more complex workflows in supply chain and multi function HR systems could test execution, a risk for new AI heavy use cases

    60% confidence

  • ServiceNow is being adopted as an AI-driven enterprise platform by new ecosystem partners and customers

    60% confidence

  • These are not lightweight plug-ins but full deployments aimed at coordinating real-world processes such as logistics, employee services, and IT incidents

    60% confidence

  • These are deep, system-of-record style integrations rather than one-off point tools

    60% confidence

  • ServiceNow aims to be an AI workflow platform at the center of large enterprises

    60% confidence

  • ServiceNow is being used as a common control layer for AI-powered workflows across supply chain, IT operations, security and HR

    60% confidence

Data points we hold from this source

ServiceNow · risk count0 count
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com
ServiceNow Partnerships Deepen AI Workflow Role Across Supply Chain And HR — Source | Via News | Via News